US equities |
INTC $64.55 ▼-29.90% AMZN $238.94 ▼-1.99% MU $881.37 ▼-5.66% NVDA $205.08 ▼-4.02% SNDK $1,168.93 ▼-12.11% GOOGL $281.99 ▼-0.64% SPCX $138.42 ▼-3.80% AMD $507.46 ▼-10.41%
FinancialContent

Biomea Fusion, Inc. - Common Stock (NQ:BMEA)

0.6100 -0.0100 (-1.61%)
Delayed Quote Updated: 12:10 PM EDT, Oct 30, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Biomea Fusion, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
News headline image
Biomea Fusion Announces KOL Presentation and Interview on Menin and Icovamenib at WCIRDC 2025
From Biomea Fusion, Inc.
Via GlobeNewswire
News headline image
Biomea Fusion Presents COVALENT-111 Study Results at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)
Durable Glycemic and C-Peptide Improvements with Icovamenib in Insulin-Deficient Type 2 Diabetes 
From Biomea Fusion, Inc.
Via GlobeNewswire
News headline image
Which stocks are moving after the closing bell on Tuesday? ↗
Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements. 
Via Chartmill
News headline image
Biomea Fusion Announces Oral Presentation of Icovamenib at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)
From Biomea Fusion, Inc.
Via GlobeNewswire
News headline image
Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
From Biomea Fusion, Inc.
Via GlobeNewswire
News headline image
Biomea Fusion to Participate at Upcoming Investor Conferences
From Biomea Fusion, Inc.
Via GlobeNewswire
News headline image
Biomea Fusion to Participate at Jefferies London Healthcare Conference
From Biomea Fusion, Inc.
Via GlobeNewswire
News headline image
Biomea Fusion Showcases Preclinical Advances for BMF-650 and Icovamenib with Low Dose Semaglutide at ObesityWeek® 2025
From Biomea Fusion, Inc.
Via GlobeNewswire
News headline image
Biomea Fusion Reports Third Quarter 2025 Financial Results and Corporate Highlights
From Biomea Fusion, Inc.
Via GlobeNewswire
News headline image
Biomea Fusion to Present Poster Presentations at ObesityWeek®2025
From Biomea Fusion, Inc.
Via GlobeNewswire
News headline image
Biomea Fusion Announces First Patient Dosed in Phase I Study of BMF-650 a Next-Generation Oral GLP-1 Receptor Agonist
Initial Clinical Data Expected in the First Half of 2026 
From Biomea Fusion, Inc.
Via GlobeNewswire
News headline image
Biomea Fusion to Participate in Citi's SMID Biotech C-Suite Fireside Chat Series
From Biomea Fusion, Inc.
Via GlobeNewswire
News headline image
Top stock movements in today's session. ↗
Intrigued by the market activity one hour before the close of the markets on Tuesday? Uncover the key winners and losers of today's session in our insightful analysis. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
Which stocks are moving on Tuesday? ↗
Curious about what's happening in today's session? Check out the latest stock movements and price changes. 
Via Chartmill
News headline image
Biomea Fusion Stock Plummets Following Public Offering, Diabetes Study ↗
Biomea Fusion reported favorable safety for icovamenib in a 52-week diabetes study, alongside a $25 million public offering. 
Via Benzinga
News headline image
Tuesday's session: gap up and gap down stocks ↗
The session on Tuesday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session. 
Via Chartmill
News headline image
Dow Jumps Over 100 Points; McCormick Earnings Top Views ↗
 
Via Benzinga
Topics Stocks
News headline image
Stay updated with the stocks that are on the move in today's pre-market session. ↗
Before the opening bell on Tuesday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Biomea Fusion Announces Pricing of Public Offering of Securities
From Biomea Fusion, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
 
Via Benzinga
News headline image
Biomea Fusion Announces Proposed Public Offering of Securities
From Biomea Fusion, Inc.
Via GlobeNewswire
News headline image
Biomea Fusion Announces Positive 52-Week Results from Phase II COVALENT-111 Study in Type 2 Diabetes Demonstrating Non-Chronic Treatment with Icovamenib Benefits Two Distinct Patient Populations
From Biomea Fusion, Inc.
Via GlobeNewswire
News headline image
Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
From Biomea Fusion, Inc.
Via GlobeNewswire
News headline image
Biomea Fusion Presents Data Demonstrating Enhanced Preclinical Activity of Icovamenib in Combination with Semaglutide in Type 2 Diabetes (T2D) Animal Model at the 61st EASD Annual Meeting and Provides Additional Corporate Update
From Biomea Fusion, Inc.
Via GlobeNewswire
News headline image
This Oddity Tech Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday ↗
 
Via Benzinga
News headline image
Biomea Fusion (BMEA) Q2 Loss Drops 44% ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Biomea Fusion Reports Second Quarter 2025 Financial Results and Corporate Highlights
From Biomea Fusion, Inc.
Via GlobeNewswire
News headline image
Biomea Fusion Appoints Julianne Averill to its Board of Directors
From Biomea Fusion, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >